Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Iradimed (IRMD) Cost of Revenue (2016 - 2026)

Iradimed has reported Cost of Revenue over the past 14 years, most recently at $4.1 million for Q1 2026.

  • Quarterly Cost of Revenue fell 13.2% to $4.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $17.8 million through Mar 2026, down 1.41% year-over-year, with the annual reading at $17.4 million for FY2025, 3.13% up from the prior year.
  • Cost of Revenue was $4.1 million for Q1 2026 at Iradimed, down from $4.6 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $6.6 million in Q4 2023 and troughed at $793716.0 in Q1 2023.
  • The 5-year median for Cost of Revenue is $4.1 million (2026), against an average of $3.9 million.
  • Year-over-year, Cost of Revenue plummeted 74.14% in 2023 and then skyrocketed 430.47% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $3.7 million in 2022, then soared by 79.84% to $6.6 million in 2023, then decreased by 12.11% to $5.8 million in 2024, then dropped by 20.53% to $4.6 million in 2025, then dropped by 11.98% to $4.1 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Cost of Revenue are $4.1 million (Q1 2026), $4.6 million (Q4 2025), and $4.7 million (Q3 2025).